WO2015092444A3 - Biomarkers - Google Patents

Biomarkers Download PDF

Info

Publication number
WO2015092444A3
WO2015092444A3 PCT/GB2014/053831 GB2014053831W WO2015092444A3 WO 2015092444 A3 WO2015092444 A3 WO 2015092444A3 GB 2014053831 W GB2014053831 W GB 2014053831W WO 2015092444 A3 WO2015092444 A3 WO 2015092444A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
treatment
igf
inhibitors
disease
Prior art date
Application number
PCT/GB2014/053831
Other languages
French (fr)
Other versions
WO2015092444A2 (en
Inventor
Valentine MACAULAY
Shan Gao
Christopher Lord
Alan Ashworth
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2015092444A2 publication Critical patent/WO2015092444A2/en
Publication of WO2015092444A3 publication Critical patent/WO2015092444A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Biomarkers are provided herein that are useful in predicting patient responses to treatment of disease, and to related assays using those biomarkers. Biomarkers provided herein are capable of identifying patients who will benefit from treatment with IGF-1R inhibitors.
PCT/GB2014/053831 2013-12-20 2014-12-22 Biomarkers WO2015092444A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1322783.0 2013-12-20
GB201322783A GB201322783D0 (en) 2013-12-20 2013-12-20 Biomarkers

Publications (2)

Publication Number Publication Date
WO2015092444A2 WO2015092444A2 (en) 2015-06-25
WO2015092444A3 true WO2015092444A3 (en) 2015-09-17

Family

ID=50071313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/053831 WO2015092444A2 (en) 2013-12-20 2014-12-22 Biomarkers

Country Status (2)

Country Link
GB (1) GB201322783D0 (en)
WO (1) WO2015092444A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109490543B (en) * 2018-11-26 2021-08-31 复旦大学附属金山医院 Kit for predicting gastrointestinal stromal tumor drug resistance and application thereof
CN111411154B (en) * 2020-03-16 2021-01-15 中国科学院苏州生物医学工程技术研究所 Biomarkers and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213284A1 (en) * 2002-05-28 2007-09-13 Muhammad Sohail Method of selecting targets for gene silencing by RNA interference
US20090093488A1 (en) * 2007-10-03 2009-04-09 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213284A1 (en) * 2002-05-28 2007-09-13 Muhammad Sohail Method of selecting targets for gene silencing by RNA interference
US20090093488A1 (en) * 2007-10-03 2009-04-09 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2013134649A1 (en) * 2012-03-09 2013-09-12 Verastem, Inc. Biomarkers for cancer stem cells and related methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALI MOHAMED ET AL: "Targeted Therapy for Breast Cancer", THE AMERICAN JOURNAL OF PATHOLOGY, VOL. 183, NO. 4, 1 October 2013 (2013-10-01), pages 1096 - 1112, XP055122092, Retrieved from the Internet <URL:http://ac.els-cdn.com/S0002944013005269/1-s2.0-S0002944013005269-main.pdf?_tid=0c853b0e-ed57-11e3-a466-00000aacb35d&acdnat=1402044568_a89ac6e942c9be1de671e2b10d55176f> [retrieved on 20140606] *
HUANG FEI ET AL: "The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 69, no. 1, 1 January 2009 (2009-01-01), pages 161 - 170, XP002570082, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-08-0835 *
S. GAO ET AL: "Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling", CANCER RESEARCH, vol. 74, no. 20, 15 October 2014 (2014-10-15), pages 5866 - 5877, XP055172242, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-14-0806 *
W. R. WIEDEMEYER ET AL: "Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 25, 22 June 2010 (2010-06-22), pages 11501 - 11506, XP055172216, ISSN: 0027-8424, DOI: 10.1073/pnas.1001613107 *

Also Published As

Publication number Publication date
WO2015092444A2 (en) 2015-06-25
GB201322783D0 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
ZA201605844B (en) Clinical outcome tracking and analysis
EP3091074A4 (en) T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
EP3065777A4 (en) Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
EP2971128A4 (en) Biomarkers for diagnosis of lung diseases and methods of use thereof
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EP2973121A4 (en) Systems and methods for disease associated human genomic variant analysis and reporting
EP3186397A4 (en) Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2015013166A (en) Dual specific binding proteins directed against il-1 beta and il-17.
EP2997162A4 (en) Methods for diagnosing and treating inflammatory bowel disease
EP2841599A4 (en) Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method.
EP3024482A4 (en) Methods for diagnosing and treating immune disease
EP3122906A4 (en) Hpv16 antibodies as diagnostic and prognostic biomarkers in pre-invasive and invasive disease
EP3087926A4 (en) Ultrasound or photoacoustic probe, ultrasound diagnosis system using same, ultrasound therapy system, ultrasound diagnosis and therapy system, and ultrasound or photoacoustic system
EP3013425A4 (en) Treatment and diagnosis of ocular disease
FR2979346B1 (en) NANOCORPS ANTI-VCAM-1
EP3088895A4 (en) Method for analyzing information for diagnosis and kit therefor
WO2014166303A3 (en) Use of multiomic signature to predict diabetes
EP3044321A4 (en) New marker for the classification, diagnosis and treatment of scoliosis
WO2015092444A3 (en) Biomarkers
EP3052660A4 (en) Kits and methods for diagnosis, screening, treatment and disease monitoring
EP3088896A4 (en) Method for analyzing information for diagnosis and kit therefor
BR112015002867A2 (en) devices and methods for securing medical devices within an anatomy.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14820929

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 20.10.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14820929

Country of ref document: EP

Kind code of ref document: A2